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ABSTRACT
Background To evaluate the safety, tolerability, 
pharmacokinetics and pharmacodynamics of eftilagimod 
alpha (efti), a soluble lymphocyte activation gene-3 protein, 
in combination with the programmed cell death-1 (PD-1) 
antagonist pembrolizumab.
Methods The study was divided into two parts; parts 
A and B, where part A was the dose escalation part 
and part B was an extension part of the study. Patients 
with metastatic melanoma were treated with efti plus 
the standard dose of pembrolizumab. Blood samples 
were assayed to determine plasma pharmacokinetic 
parameters, detect efti antibody formation and determine 
long- lived CD8 T cell responses and associated 
pharmacodynamic parameters.
Results Twenty- four patients with melanoma received 
pembrolizumab and bi- weekly subcutaneous (s.c.) 
injections of efti at doses 1 mg, 6 mg or 30 mg/injection 
for up to 6 months (part A) or 30 mg/injection for up 12 
months (part B). No dose- limiting toxicities were reported 
and the main adverse event for efti was injection site 
reactions. Sustained systemic exposure to the product was 
obtained in all patients following s.c. injections of 30 mg 
dose. Treatment induced an increase in activated CD8 and 
CD4 T cell counts, and in some of the soluble biomarkers, 
particularly interferon (IFN)-γ, a Th1 signature cytokine. 
An overall response rate (ORR) of 33% was observed in 
patients partly with pembrolizumab- refractory of part A 
and ORR of 50% was observed in patients with PD-1 naïve 
of part B.
Conclusions Efti was well tolerated in combination with 
pembrolizumab with encouraging antitumor activity. This 
warrants further clinical studies of this new combination 
therapy combining an antigen- presenting cell activator 
with an immune checkpoint inhibitor.
INTRODUCTION
Antigen- presenting cell (APC) activators 
are a type of immunotherapy that lever-
ages APC to drive an adaptive immune 
response. Combinatorial approaches that 
target multiple aspects of the cancer immu-
nity cycle,1 including APC activation, are 
promising strategies for the treatment of 
cancer. Professional APCs express major 
histocompatibility complex (MHC) class II 
and CD40 molecules as surface receptors 
and can be activated through direct interac-
tions with T cells expressing these receptors’ 
corresponding ligands, lymphocyte activation 
gene-3 (LAG-3) and CD40- L, respectively. 
A third class of receptors that can activate 
APCs are called toll- like receptors (TLRs) 
and bind foreign ligands that are structurally 
conserved molecules from microbes. Interest 
in the clinical use of TLR and CD40 agonistic 
antibodies in immuno- oncology wavered in 
the past decade,2 but recent clinical data are 
encouraging.3–5
The MHC class II agonist eftilagimod 
alpha (efti, IMP321 or LAG- 3Ig) is a soluble 
LAG-3 protein that activates APC leading 
to CD8 T- cell activation.6–8 Efti binds to a 
subset of MHC class II molecules expressed 
in plasma membrane lipid rafts on immature 
human dendritic cells (DCs) and induces 
rapid morphological changes, including 
the formation of dendritic projections.6 7 It 
also markedly upregulates the expression of 
costimulatory molecules and the production 
of IL-12 and tumor necrosis factor (TNF)-
α.6 7 In patients with cancer, efti has been 
shown to sustain the generation and expan-
sion of tumor antigen (melan- A/melanoma 
antigen recognized by T cells 1 (MART-1) 
and survivin)- specific CD8+ T lymphocytes in 
peripheral blood mononuclear cells (PBMC), 
showing its ability to boost CD8+ T cell 
memory response ex vivo.9 Phenotype and 
cytokines/chemokines produced by APC of 
PBMC exposed ex vivo for 2 days to peptide 
and efti indicate that the LAG-3- mediated 
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The addition of pembrolizumab as an immune check-
point inhibitor (ICI) aims at enhancing activity by 
combining efti’s activating effects on immune cells with 
the release of immune inhibitory effects caused by inter-
ruption of the programmed death-1 (PD-1)/programmed 
death ligand-1 axis. The present TACTI- mel (“Two 
ACTive Immunotherapies in melanoma”) phase I trial is 
testing this combined push (systemic APC activation) and 
pull (ICI) approach in metastatic melanoma. This ther-
apeutic approach is fundamentally different from the 
mainstream two- ICI approach (ie, anti- LAG-3+anti- PD-1 
monoclonal antibody (mAbs)) as efti is an agonist acting 
on APC and anti- LAG-3 mAb is an antagonist acting on T 
cells, see figure 1.
MATERIALS AND METHODS
Study design and treatments
This was a multicenter, open- label, dose escalation, phase 
I study in patients with unresectable or metastatic mela-
noma receiving efti in combination with anti- PD-1 therapy 
with pembrolizumab.
In part A, screening was done in parallel to cycle 4 of 
actively ongoing pembrolizumab therapy and treatment 
with efti was started with cycle 5 of pembrolizumab. 
Pembrolizumab was given at a dose of 2 mg/kg intrave-
nous every 3 weeks; efti was given as subcutaneous (s.c.) 
injection of 1 mg (cohort 1), 6 mg (cohort 2) or 30 mg 
(cohort 3) every 2 weeks for approximately 6 months, 
starting with cycle 5 of pembrolizumab. The study design 
for part A is shown in figure 2.
Three sequential dose escalation cohorts of six patients 
each were evaluated for dose- limiting toxicities (DLTs) 
according to Common Terminology Criteria for Adverse 
Events (CTCAE) V.4.03. The evaluation for DLTs was 
performed in the safety observation period (from the 
first study treatment until 24 hours after the third efti 
injection). Decisions for dose escalation and determi-
nation of the recommended dose for part B were based 
on all safety data collected during the safety observation 
period and made by the Data and Safety Monitoring 
Board.
In part B, patients received pembrolizumab (2 mg/
kg intravenous every 3 weeks) in conjunction with efti 
s.c. at the recommended dose of 30 mg every 2 weeks 
for a maximum of 12 months, starting with cycle 1 of 
Figure 1 Effect of efti versus an anti- LAG-3 antagonist 
antibody on the immune response. LAG-3, lymphocyte 
activation gene-3.
Figure 2 Study design of parts A and B. Tumor assessment was done every 12 weeks in both parts. Pembrolizumab could 
be continued after combination therapy with efti was finished. Pembrolizumab was administered intravenous 2 mg/kg. efti was 
administered s.c. Part A (top): patients with irPD or suboptimal response (ie, irSD or PR) after 3 cycles of pembrolizumab were 
screened during cycle 4 of pembrolizumab therapy. Eligible patients received efti (1, 6, 30 mg) with cycle 5 of pembrolizumab for 
up to 6 months. Part B (bottom): patients received efti (30 mg) with cycle 1 of pembrolizumab for up to 12 months. ORR, overall 
response rate; PFS, progression- free survival; TACTI, Two ACTive Immunotherapies.
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pembrolizumab treatment. Patients were also evaluated 
for DLTs according to CTCAE V.4.03.
Study assessments
The primary objective of the study was to evaluate the 
safety, tolerability and recommended phase two doseof 
efti when combined with anti- PD-1 treatment starting 
with cycle 5 (part A) or cycle 1 (part B) of pembroli-
zumab. The primary endpoint was safety as defined by the 
frequency, severity and duration of adverse events (AEs) 
including serious AEs (SAEs) and DLTs and other safety 
parameters.
Tumor response and progression were assessed using 
immune- related response criteria (irRC) and Response 
Evaluation Criteria in Solid Tumors (RECIST V.1.1) with 
imaging studies done every 12 weeks. Blood samples were 
collected for analysis of plasma concentrations of efti and 
cytokines/chemokines and for detection of serum anti- 
efti antibodies. EDTA- whole blood samples were collected 
for monitoring the T cell immune responses.
Pharmacokinetic analysis
Pharmacokinetic analysis was performed using a validated 
method on plasma samples collected up to 48 hours post 
the 1st and 13th efti dosing in the dose escalation part. 
Efti concentration was assessed using an LAG-3- specific 
ELISA using a pair of mouse monoclonal anti- human 
LAG-3 antibodies, 11E3 and biotin- conjugated 17B4 as 
capture and detection reagent, respectively. The lower 
limit of quantification was determined at 105 pg/mL. 
Pharmacokinetic parameters were derived using noncom-
partmental analysis with Phoenix WinNonlin V.7.0 soft-
ware (Certara).
Cytokines/chemokines assessment
Panels of 9 cytokines and 10 chemokines were assessed in 
plasma samples collected prior and 1, 2, 4, 8, 24 and 48 
hours post the 1st and the 13th efti administration in part 
A patients. In outline, the analytical method consists of a 
validated multiplexed electrochemiluminescence immu-
nosorbent assay (ECLIA) using commercial kits (human 
proinflammatory panel 1 and chemokines panel 1 V—
plex MesoScale Discovery kits). Manufacturer instructions 
were followed with minor modifications and lower limits 
of quantification were determined at 6.1, 1.6, 5.3, 0.8, 0.7, 
0.7, 0.5, 2.9, 7.5, 1.3, 7.5, 34.2, 3.5, 6.4, 9.8, 2.4, 3.7, 27.6, 
8.2 pg/mL for interferon (IFN)-γ, IL-1β, IL-2, IL-4, IL-6, 
IL-8, IL-10, IL- 12p70, IL-13, TNF-α, eotaxin, eotaxin-3, 
Thymus and activation- regulated chemokine (TARC), 
Interferon gamma- induced protein 10 (IP-10), Macro-
phage inflammatory protein (MIP)-1α, MIP-1β, Monocyte 
chemoattractant protein (MCP)-1, Macrophage- derived 
chemokine (MDC) and MCP-4, respectively.
Detection of anti-efti antibodies
Serum samples were planned pretreatment and at end 
of treatment visit for all patients. Additionally, patients 
participating to the part B of the study were sampled 
after about 1, 2, 3, 6 and 9 months at cycles 2, 3, 5, 9, 13 
always predose. A fully validated three tiers conventional 
bridging ECLIA method with a screening assay (tier 1), 
a confirmatory assay (tier 2) and titration assay (tier 3) 
were used. Briefly, anti- efti antibodies were captured 
and detected in a sandwich formed by biotinylated and 
ruthenylated efti. Such complexes are then captured by 
a streptavidin- coated plate and processed for ECL signal 
detection. An affinity purified rabbit anti- LAG-3 poly-
clonal antibody was used as positive control. The sensi-
tivity was determined at 78 ng/mL in a pooled serum 
matrix and confirmed at 250 ng/mL in 20 individual 
serum. The free drug tolerance was found to be approxi-
mately 500 ng/mL of free drug for 250 ng/mL of positive 
control. Thus, given the low level of circulating drug (<20 
ng/mL), drug tolerance was acceptable for the intended 
purpose.
Pharmacodynamics
EDTA- whole blood samples were collected at cycle 1, cycle 
5, cycle 9 and cycle 13 (in part B only) prior to treatment 
(therefore 2 weeks after the previous dosing) and EOT. 
Direct blood staining with BD Multitest CD8- FITC (clone 
SK1)/CD38- PE (clone HB7)/CD3- PerCP (clone SK7)/
HLA- DR- APC (clone L343) was performed to enumerate 
ex vivo the absolute counts of activated T CD3+CD8+ or 
CD3+CD8- cells coexpressing HLA- DR and CD38 in BD 
Trucount tube with a lyse/no wash procedure, avoiding 
any bias induced by centrifugation steps. Cells were 
acquired on BD FACSCanto II flow cytometer. The paired 
nonparametric Wilcoxon- signed rank test was used to 
compare the immunomonitoring results obtained at the 
different time points to the pre- treatment baseline using 
JMP V.12 software.
In vitro antigenic T-cell response assessment
PBMCs from healthy donors (0.2×106 cells/well in 
round- bottom 96- well plate, at 1×106/mL in complete 
RPMI+10% fetal calf serum) incubated with a pool of 
peptides covering the sequence of cytomegalovirus (CMV) 
pp65 in triplicate (PepTivator CMV pp65 form Miltenyi 
Biotec), with or without efti and/or an antagonist anti- 
PD-1 antibody (clone EH12.1, BD Biosciences) as indi-
cated in figure 2 legend in complete RPMI. After 2 days, 
cells and/or supernatant were collected and cytokines/
chemokines were assessed by Cytometric Bead Array flex 
set (BD Biosciences) to measure concentrations of cyto-
kines in the supernatant. In other series of experiments, 
PBMCs were stimulated as above and cells were collected 
to be stained with a mix of the following conjugated anti-
bodies to determine expression of activation markers. 
Anti- CD14- APC (clone MφP9), Anti- CD4- PerCPCy5.5 
(clone L200), anti- CD8- PE (clone RPA- T8), anti- CD25- 
PECy7 (clone M-251), anti- CD69- APCCy7 (clone FN50) 
were purchased from BD Biosciences. Antibody staining 
was performed at 4°C during 30 min in phosphate buff-
ered saline (PBS), bovine serum albumine (BSA) 0.5%, 
azide 0.1%. Data were collected on a FACS Canto A and 
CD14−CD8+ and CD14−CD4+ gated populations were 
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analyzed on DIVA software (BD Biosciences). Compari-
sons of combined cell treatment to treatment with single 
agents were analyzed by Student’s t- test.
Statistical analysis
Safety: Analyses of safety parameters were performed 
using descriptive statistics.
Efficacy: Assessments of tumor response were based 
on investigator assessment according to Guidelines 
for the Evaluation of Immune Therapy Activity in 
Solid Tumors: irRC/RECIST V.1.1. Analyses of tumor 
response endpoints were performed based on uncon-
firmed responses (main analysis) and additionally also on 
confirmed responses, for both RECIST V.1.1 and irRC. 
In parts A and B, response was assessed using as baseline 
the start of pembrolizumab and efti combination therapy. 
Additional exploratory analyses were performed for part 
A, using the start of pembrolizumab treatment as base-
line. For this exploratory immune related Best Overall 
Respons (irBOR), the sum of target lesions prior to 
pembrolizumab therapy initiation was used as a reference 
for each patient.
Efficacy analyses and exploratory endpoints were gener-
ally performed using descriptive statistics. Progression- 
free survival (PFS) was analyzed using Kaplan- Meier 
methods.
RESULTS
In vitro proof-of-concept for combined therapy (anti-PD-
1+efti)
The combination of efti as an APC- activator with an ICI 
to boost the immune response was evaluated in vitro by 
monitoring the antigenic T- cell response of human PBMC 
stimulated with an antigenic peptides pool in the pres-
ence of efti and anti- PD-1 antibody. Cellular response was 
monitored by assessing the concentration of IFN-γ, TNF-α 
and RANTES in cell supernatants or the expression of 
activation markers (CD69, CD25) on CD8 T cell surface 
(figure 3). High concentration (1000 ng/mL) of anti- 
PD-1 antibody was also used as additional control. The 
immune response induced by the combination of efti and 
anti- PD1 antibody was more pronounced as fold increase 
than the sum of the effects obtained after incubation with 
a single agent. The response to combined treatment was 
also greater than the one observed with PD-1 blocker at 
30- fold higher concentration. The effect of efti addition 
in an anti- PD-1 antibody dose–response experiment led 
to a similar observation (figure 3C).
Patients
The study was divided into two parts; parts A and B, 
where part A was the dose escalation part and part B was 
a dose confirmation part of the study. Patients were to 
stay on treatment until confirmed disease progression, 
Figure 3 Effect of efti plus anti- PD-1 combination on antigen- induced human T cell response. CMV- stimulated PBMCs from 
healthy donors were incubated in the presence of 0 or 30 ng/mL efti and in the presence of 0, 30 or 1000 ng/mL anti PD-1 
antagonist antibody as indicated. Two days post- stimulation, supernatants were collected and concentration of IFN-γ, TNF-α 
and RANTES was measured (A). The expression of activation markers, CD69 and CD25 at the surface of CD8+ T cells was 
analyzed by flow cytometry (B). The results are shown in fold increase of levels of soluble biomarkers or the % of CD8 T cells 
expressing the indicated marker in the indicated condition to the value obtained in the absence of efti and anti- PD-1 antibody. 
Bars represent average of 10 donors for soluble analytes and seven donors for activation markers. Significant difference 
(p<0.05) between combined condition to either efti or anti- PD-1 Ab alone is displayed by a bar on the top of each graph. 
Panel (C) shows the IFN-γ concentration in cell supernatants of an anti- PD-1 dose–response experiment, either alone (opened 
markers, dashed lines) or combined with 30 ng/mL efti (close markers, plain lines), carried out with PBMC from three donors. 
The results are shown in fold increase of IFN-γ levels as a function of anti- PD-1 antibody concentration. CMV,cytomegalovirus; 
IFN, interferon; PBM, peripheralblood mononuclear; PD-1, programmed death-1.
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unacceptable toxicity, completion of the study or discon-
tinuation for any other reason whichever occurred first. 
The study was conducted at seven sites across Australia. 
Main inclusion criteria were histologically confirmed 
unresectable stage III or stage IV melanoma; Eastern 
Cooperative Oncology (ECOG) 0–1; measurable disease 
according to RECIST 1.1 and adequate laboratory values. 
Main exclusion criteria were prior PD-1/programmed 
death ligand-1 (PD- L1) therapy (for part A, patients were 
on pembrolizumab therapy at the time of screening), 
known cerebral or leptomeningeal metastases (stable 
previously treated brain metastases allowed) or contin-
uous corticotherapy (>10 mg/day prednisone equiva-
lent) within 4 weeks prior to study start.
Part A
Eighteen patients were included in part A of the study. All 
patients had stage IV melanoma. Disease stage at baseline 
was M1c in 14 patients (77.8%), M1b in 3 patients (16.7%) 
and M1a in 1 patient (5.6%). In 38.9% of patients, lactate 
deshydrogenase (LDH) was elevated at study entry. Of 
27.8% had received prior anticancer medications, that 
is, three patients had received dabrafenib and trametinib 
and two patients had received ipilimumab. All patients 
of part A were receiving pembrolizumab at the time of 
screening. ECOG PS at screening was 0 in 14 patients 
(77.8%) and 1 in 4 patients (22.2%). Almost all patients 
(94.4%) were men; all patients were Caucasian. Median 
age was 66.7 years. Patients were required to have asymp-
tomatic immune- related progressive disease (ie, slowly 
progressive disease, not requiring urgent intervention and 
stable performance status) or suboptimal response (ie, 
immune- related stable disease (irSD) or partial response 
(irPR)) after three cycles (≈9 weeks) of pembrolizumab.
Part B
Part B was a six- patient toxicity lead- in cohort. All patients 
had stage IV melanoma. Stage of disease was M1c in four 
patients (66.7%) and M1b in two patients (33.3%). In 
80% of patients, LDH was elevated at study entry. ECOG 
PS at screening was 0 and 1 in three patients (50.0%) each. 
Almost all (five patients, 83.3%) were men; all patients 
were Caucasian. Median age was 65.0 years. Most patients 
(83.3%) had undergone prior anticancer surgery; one 
(16.7%) had received prior anticancer radiation; none 
had received prior systemic anticancer medication.
Safety
Part A
The planned number of 13 efti doses was given in six 
patients (33%). Main reason for discontinuation was 
progression (n=7; 39 %). The median number of efti 
injections was 8 in the 1 mg and 6 mg cohorts and 12 
in the 30 mg cohorts. Median treatment duration with 
efti was 98 days in the 1 mg and 6 mg cohorts and 161 
days in the 30 mg cohort. No DLTs were reported. None 
of the AEs led to discontinuation of efti or pembroli-
zumab. SAEs were reported in six patients (33%); none 
as being drug related. The most frequent AEs regardless 
of relationship are listed in table 1. Nine patients (50.0%) 
reported AEs (possibly) related to efti. AEs reported 
in more than single patients were fatigue (11.1%) and 
rash (11.1%). Thirteen patients (72.2%) reported AEs 
(possibly) related to pembrolizumab. AEs reported in 
more than single patients were fatigue (27.8%), nausea 
(16.7%), diarrhea (11.1%,), pruritus (11.1%), arthralgia 
(11.1%), colitis (11.1%) and rash (11.1%).
Part B
Of six patients, three patients (50%) received all 27 doses 
of efti according to the protocol. Two patients discon-
tinued due to progressive disease and one due to an 
AE. The median number of injections in part B was 24. 
Median treatment duration with efti in part B was 322 
days. DLTs were not reported. One SAE of anaphylactic 
reaction (grade 3) was judged as efti related; this patient 
discontinued efti because of the event. The most frequent 
AEs regardless of relationship are listed in table 1. Five 
patients (83.3%) reported AEs (possibly) related to efti. 
AEs reported in more than single patients were injection 
site erythema (66%), injection site swelling (50%) and 
injection site pain (33%). Five patients (83.3%) reported 
AEs that were (possibly) pembrolizumab related. AEs 
Table 1 Most frequent (≥4 or more patients in part A and/or >3 pts in part B) treatment- related adverse events











Fatigue 4 (66.7) 1 (16.7) 3 (50.0) 8 (44.4) 5 (83.3)
Injection site erythema – – 1 (16.7) 1 (5.6) 4 (66.7)
Edema peripheral – – – – 4 (66.7)
Diarrhea 2 (33.3) – 3 (50.0) 5 (27.8) 1 (16.7)
Nausea 1 (16.7) 2 (33.3) 2 (33.3) 5 (27.8) 2 (33.3)
Rash 1 (16.7) 2 (33.3) 2 (33.3) 5 (27.8) 4 (66.7)
Arthralgia 2 (33.3) 1 (16.7) 1 (16.7) 4 (22.2) 4 (66.7)
Results shown as: number of patients with adverse event (%).
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reported in more than single patients were rash (50%); 
and fatigue, arthralgia and pruritus (each 33%).
Pharmacokinetic analysis
A dose- proportional maximal exposure was observed 
across all dose levels. The results of the pharmacokinetics 
analysis for the three dose groups are shown in figure 4. 
After administration of efti 30 mg, all patients reached 
a circulating plasma concentration of efti/soluble LAG-3 
(sLAG-3)>1 ng/mL, while only half of the patients 
receiving efti 6 mg and none from the efti 1 mg cohort 
reached this threshold. Mean Cmax increased with dose 
(for both cycles): 0.26 ng/mL (n=6, 35% CV) for efti 1 
mg, 1.95 ng/mL (n=6, 88% CV) for efti 6 mg and 3,52 
ng/mL (n=6, 71% CV) for efti 30 mg, in cycle 1. These 
values are similar to the ones reported previously with efti 
monotherapy.10 In cycle 9, values of 0.24 ng/mL (n=2, 1% 
CV) for efti 1 mg, 0.78 ng/mL (n=2, 0.4% CV) for efti 6 
mg and 3.43 ng/mL (n=3, 85% CV) for efti 30 mg were 
reported.
At first administration, median Tmax was about 14 
hours for efti 1 mg and 6 mg and 24 hours for efti 30 
mg. In cycle 9, median Tmax decreased with dose: 24.0 
hours, 12.6 hours and 4.0 hours for efti 1 mg, 6 mg and 
30 mg, respectively. Mean area under the curve (AUC)0- t 
was 9195 hour·pg/mL (n=6, 58% CV) for efti 1 mg, 65 
674 hour·pg/mL (n=6, 103% CV) for efti 6 mg and 110 
753 hour·pg/mL (n=6, 69% CV) for efti 30 mg, in cycle 
1; and 6883 hour·pg/mL (n=2, 61% CV) for efti 1 mg, 16 
213 hour·pg/mL (n=2, 115% CV) for efti 6 mg, and 92 
036 hour·pg/mL (n=3, 94% CV) for efti 30 mg, in cycle 9.
Safety cytokines/chemokines and anti-efti antibodies
Study treatment- related clinically relevant increases of 
plasma levels of at least two cytokines among TNF-α, 
IFN-γ, IL-1β, IL-2, IL-4 and IL-8 by >50 times over base-
line were considered as DLT. No safety- related increase 
in circulating levels cytokines was noted for any patient. 
A moderate increase in IL-6 (mean fold change 1.5, 1.7 
and 1.6 at 4, 8 and 24 hours, respectively, after the first 
dosing at cycle 1, and 1.8, 1.8 and 1.4 at 4, 8 and 24 hours, 
respectively, after the last dosing at cycle 9) was observed.
In part A, the percentage of anti- drug antibodies (ADA)- 
positive patients increased with the efti dose. In part B, all 
patients treated for at least 2 months were ADA- positive. 
Relatively high titres were observed in two patients of six 
(up to 666), while other patients had low titer (<32). No 
obvious relationship could be observed between immu-
nogenicity and pharmacodynamics parameters. ADA 
occurrence and intensity did not negatively impact the 
clinical response read- outs.
Pharmacodynamics
Immunomonitoring was done on whole blood samples 2 
weeks after efti injection in order to detect the minimal 
residual effect of efti just before the next efti injection. 
Therefore, any change induced by efti would indicate a 
long- term sustained immunostimulation (more than 10 
days after efti disappearance in the blood) and for the 
T- cell compartment a sustained effect on the memory 
T- cell subset.
In part B, which is the study design to be used for future 
phase II trials, we found a sustained increase in activated 
(CD38+ HLA- DR+) CD4 T cells (1.3, 1.5 and 1.2- median 
fold or 1.4, 1.6 and 1.2- mean fold change at day 1 of cycle 
5, day 1 of cycle 9 and day 1 of cycle 13, respectively) 
or CD8 T cells (2.1, 2.0 and 1.8- median fold or 2.5, 2.0, 
1.5- mean fold change) counts compared with the base-
line (predose at cycle 1) (figure 5). All part B patients 
increased their circulating activated cytotoxic T cells by at 
least two- fold after 3 months of treatment and by at least 
1.5- fold after 6 months, while in part A, only 4 patients 
out of 11 tested showed an increase by more than 1.5- fold 
at cycle 5 or cycle 9. Among these 4, 3 received 30 mg 
doses (online supplemental figure 1). An increase in NK 
cell counts was also observed in part B patients with 1.7- 
median fold or 1.6- mean fold at day 1 of cycle 5 and 1.4- 
median fold or 1.5- mean fold at day 1 of cycle 9 (online 
supplemental figure 1).
In part A patients, the circulating concentrations of 
IFN-γ, a Th1 biomarker, were slightly increased at cycle 9 
prior to the last dosing, namely, 2 weeks after the previous 
efti administration, by a mean of 1.3. IFN-γ concentration 
continued to increase up to a mean fold change of 2 at 
8 hour after the last dosing of the study drug compared 
with the baseline. Chemokine (C- X- C motif) ligand 
(CXCL-10), another Th1 biomarker, only increased 1.3- 
fold, 8–48 hours following the last injection.
Efficacy
In part A, based on the start of efti and pembrolizumab 
combination therapy (see figure 3 study PFS/overall 
response rate (ORR)), six patients (33%) achieved 
ORR (RECIST1.1; unconfirmed) including two patients 
(11.1%) with a CR. Both CRs and five responses in total 
were confirmed. Disease control rate (DCR) was 55.6%. 
Median PFS according to RECIST V.1.1 was reported with 
142 days (4.7 months). The probability of being event- 
free according to RECIST V.1.1 at 12 months was 35.7%. 
The depth of responses is shown in the waterfall plot in 
figure 6B. The development over time is displayed in 
the spider plot in figure 6A. Results based on irRC were 
Figure 4 PK profiles. PK profiles from patients receiving 
1 mg (left panel), 6 mg (middle panel) or 30 mg (right panel) 
are shown. Soluble LAG-3 was measured by ELISA in the 
plasma at different time points following the first (plain lines) 
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comparable to those based on RECIST 1.1 with an irORR 
of 33 %, including one patient with irCR and five patients 
with irPR. The irDCR was 66%. Median PFS based on 
irRC was 165 days (5.4 months). The 12 months PFS rate 
was 40%. In part A, three of six patients progressing on 
pembrolizumab monotherapy benefited from the combi-
nation treatment reporting irCR (n=1), irPR (n=1) and 
irSD (n=1) as best response under study. Both patients 
with a response completed the study treatment. Of the 
six patients responding to the combination therapy, two 
were progressing, two had a stabilization of disease and 
two showed a partial response after 3 cycles of pembroli-
zumab, respectively.
In part B, ORR (RECIST V.1.1) was 50% (all confirmed) 
with a DCR of 83% (see figure 6D). All responses were 
ongoing at study end at 12+ months. Thus, median PFS 
and median duration of response could not be calculated. 
The probability of being event- free at 12 months was 67%. 
Results according to irRC were comparable with irORR 
(confirmed) was achieved by three patients (50%). irDCR 
was 67%. Median PFS (irRC) was not reached; the prob-
ability of being event free at 12 months was estimated as 
67% as shown in the spider plot in figure 6C.
Efficacy—parts A+B
Exploratory analyses were performed for pooled data 
from parts A and B (exploratory irORR/irDCR); baseline 
for all patients was the start of pembrolizumab therapy, in 
part A and part B (see figure 2). The best overall response 
per irRC for each patient of parts A and B including the 
duration of pembrolizumab treatment is shown in the 
swimmer plot in figure 7. The reported irORR was 54% 
and irDCR was 75%.
Figure 5 Increase of circulating activated cytotoxic and 
helper T cells. Absolute counts of circulating CD3+ CD8+ 
(left panel) and CD3+ CD8- (in practice CD4+ cells, right 
panel) T cells coexpressing activation markers HLA- DR 
and CD38 were counted in whole blood samples in part B, 
prior to dosing at cycle 1 (baseline), at cycles 5, 9 and 13 by 
flow cytometry. Results are presented as fold change from 
baseline at each time point. Significant changes assessed 
by paired nonparametric Wilcoxon signed rank test are 
displayed (*p<0.05, **p<0.01).
Figure 6 Best overall response. Spider plot (left; A+C) as per irRC and waterfall plot (right, B+D) as per RECIST 1.1 for part 
A (top) and part B (bottom). Best overall response (BOR) as per RECIST1.1/irRC is displayed using the following code: black 
represents PD/irPD, gray SD/irSD, hashed gray Pr/irPR while hashed black CR/irCR, respectively. *Nontarget lesions (NTL) still 
present; **target lesions (TL) and NTLs disappeared, but new lesions (NL) were present at staging; ***time of CR of TLs; NLs 
appeared; staging before was SD (BOR is SD). irPD,immune- related progressive disease; irPR, immune- related partial response; 
irSD, immune- related stable disease.
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DISCUSSION
The activation of potent CD8 T- cells with high effector 
activity is one of the goals of an effective immuno-
therapy. The data presented in this report showed a 
long- term expansion of an activated CD8 T cell subset 
in patients treated with efti and anti- PD-1 combined 
therapy. Such finding is in line with other pharmaco-
dynamic observations obtained in other efti clinical 
studies.10–13 When efti was used as a monotherapy, it 
was shown to increase the long- lived effector- memory 
CD8 T cell pool.10 CD8 T cells with memory poten-
tial are superior to terminally differentiated effector 
cells in mediating successful tumor clearance14 as the 
latter display impaired proliferation and survival in 
vivo, and only mediate short- term anti- tumor effects. 
Thus, to monitor only sustained memory T cells that 
have enhanced proliferative potential and survival and 
the potential to provide more robust and enduring 
protection against tumors, we assess CD8 T cell immu-
nological endpoints 14 days after injection of efti, that 
is, just before the next efti injection and long after efti 
has disappeared from the blood stream. We observed 
sustained increases in activated CD4 or CD8 T counts 
that are detected at 3 or 6 months in patients injected 
with 30 mg efti. These increases are different from what 
to expect from pembrolizumab monotherapy where 
activated CD8 T cell counts are increased only early on, 
at 2 or 4 weeks after start of treatment.15 Failed T cell 
priming often needs repair through APC activation16 
before successful sensitization to PD-1/PD- L1 blockade 
and MHC II agonism with efti plays a critical role in 
generating T cell immunity by activating DCs6–8
As efti or any other MHC class II agonist has not been 
tested yet in combination with an anti- PD-1 therapy, 
patients started efti injections in part A of the study 
at cycle 5 of pembrolizumab in order not to expose 
the subset of patients with pembrolizumab- induced 
immune- related AEs in the first 3 months of exposure 
to a second immunostimulant. Then, as no new safety 
signals were seen in part A, part B patients were treated 
with the combination from day 1 on. No new safety 
signals or DLTs emerged from the study data reported 
in part A or part B. Low numbers of patients reported 
injection- site reactions, which typically reappeared on 
multiple administrations, and this is consistent with the 
proposed mechanism of action (ie, APC activation of s.c 
DCs or Langerhans cells in the dermis) and the known 
safety profile of efti. There was no indication that efti 
induces immune- related AEs or increases the severity of 
pembrolizumab- related immune- related AEs.
When analyzing pooled data from parts A and B 
with the baseline at start of pembrolizumab therapy, 
the irORR was 54%. In large historical studies with 
treatment naïve KEYNOTE-006 patients, a 36% ORR, 
median PFS of 4.1 months and 47% progression free 
at 6 months were reported with pembrolizumab 
monotherapy. In patients pretreated with ipilimumab 
(KEYNOTE-002), a 21% ORR, median PFS of 2.9 
months and 34% progression free at 6 months were 
reported with pembrolizumab monotherapy.17 In the 
first phase I trial (Keynote-001), 173 melanoma patients 
pretreated with ipilimumab or BRAF/MEK inhibitor 
received pembrolizumab at 2 mg/kg or 10 mg/kg and 
the ORR was 24% in the extension part of the trial.18
Given the late stage population and pre- exposure with 
pembrolizumab prior to trial start in part A, the data 
reported here are encouraging. A phase II trial study 
testing this combination therapy in first and second- line 
non- small cell lung cancer and in second- line head and 
neck squamous cell cancer is ongoing (NCT03625323). 
In this umbrella phase II trial, patients are not selected 
for PD- L1 expression levels at the tumor site before enrol-
ment. Thus, “hot” (>50% PD- L1 expression) “tepid” (1% 
to 49% PD- L1) or “cold” (<1% PD- L1) tumor patients are 
being enrolled (ie, a PD- L1 all- comer trial).
Combination therapies are currently being evaluated 
clinically with the goal of enhancing overall antitumor 
activity, in order to provide better treatment for patients 
with large tumor burdens. The vast majority of trials is 
testing a double ICI combination (eg, an anti- CTLA-4, 
anti- LAG-3 or anti- TIGIT with an anti- PD-1), prefer-
ably in “hot” tumor patients, as blocking two inhibitory 
receptors on T cells might be better than just blocking 
one receptor. Our approach, combining an APC acti-
vator with an ICI, is different as efti, as an MHC class II 
agonist, activates T cells through an indirect and physi-
ological mechanism, that is, efti- activated APCs give the 
“license to kill”19 to CD8 memory T cells. This may result 
in more “tepid” or “cold” tumor patients responding 
to the combination therapy. The addition of efti to 
pembrolizumab induces long- term tumor responses 
and long- term increase in circulating activated CD8 
and CD4 T cell counts at the 30 mg dose. Importantly, 
this immunostimulatory effect was obtained without 
Figure 7 Swimmer plot with best overall response 
according to irRC for all patients of parts A and B. Each 
patient is displayed from the start of pembrolizumab therapy. 
All four groups are shown with A1=part A, 1 mg efti; A2=part 
A, 6 mg efti, A3=part A, 30 mg efti and B=part B, 30 mg efti. 
BOR,best overall response; irPD, immune- related progressive 
disease; irPR, immune- relatedpartial response; irSD, immune- 
relatedstable disease; PFS, progression- free survival.
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clinically significant toxicity of this first- in- class immu-
nopotentiator targeting MHC class II+ APCs
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